ABT 199 - GDC 0199 | Venetoclax
Axon 2141
CAS [1257044-40-8]
MF C45H50ClN7O7SMW 868.44
- Purity:98%
- Soluble in DMSO
Description
A highly potent, orally bioavailable BCL-2-selective inhibitor; a new Bcl-2–specific BH3 mimetic efficacious in vivo against mouse lymphomas without provoking thrombocytopenia.
KEYWORDS: ABT 199 | supplier | Bcl-2 inhibitor | GDC 0199 | Venetoclax | ABT199 | GDC0199 | ABT-199 | GDC-0199 | CAS [1257044-40-8] | Non Selective | Bcl | Inhibitor | Proteins
| AJ Souers et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19(2), 202-208. |
| C Touzeau et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia advance online publication 16 August 2013;doi: 10.1038/leu.2013.216. |
| CJ Vandenberg and S Cory. ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood, 2013, 121(12), 2285-2288. |
- Certificate of Analysis
- Material Safety Data Sheet
Chemical name
2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide
Parent CAS No.
[1257044-40-8]
Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。
暂无问答
本网站将在规定时间内给予删除等相关处理。
